Hillstar Bio: Valuation, Funding & Investors
Hillstar Bio is a biotechnology company specializing in precision immunology therapies aimed at treating autoimmune diseases. The company's innovative approach involves selectively targeting and depleting pathogenic immune cells to potentially reset the immune system, thereby offering more durable therapeutic responses. Hillstar Bio is advancing its lead TRBV9 program through clinical studies for conditions such as axial spondyloarthritis, while also progressing its broader therapeutic pipeline.
Leadership & Board
- Current Number of Employees
- 19
- Current LinkedIn Followers
- 4,106
Latest Estimated Valuation
- Total Amount Raised
- $67M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $67M
- Latest Funding Round
- Series A
Employee Trend
Hillstar Bio had 19 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Hillstar Bio had 4,106 followers as of November 16, 2026. The number of followers increased by 0 (0.00%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Mar 25, 2025 | Series A | $67.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Frazier Life Sciences | Series A |
| Novo Holdings A/S | Series A |
| Droia Ventures | Series A |
| LifeArc Ventures | Series A |
| Hummingbird Bioscience | Series A |
Similar Companies
A snapshot of private companies similar to Hillstar Bio, helping you discover and navigate related company profiles.
Related News and Analysis







